Clearside Biomedical announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX in neovascular age-related macular degeneration. Topline data results are expected in the third quarter of 2024. “As we continue to make significant progress in our ODYSSEY trial, we are optimistic about the potential benefits of CLS-AX, our proprietary suspension of axitinib for suprachoroidal injection,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. “Axitinib is a highly-potent tyrosine kinase inhibitor that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. We believe TKIs have the potential to play a significant role in the treatment of wet AMD. In ODYSSEY, we are looking to replicate the excellent safety profile, stable vision, and reduced frequency of injections we observed in our OASIS Phase 1/2a trial and its 3-month Extension Study. The differentiated mechanism of action and high potency of axitinib combined with delivery into the suprachoroidal space with our proprietary SCS Microinjector has the potential to be a best-in-class approach for long-term maintenance therapy for wet AMD patients,” concluded Dr. Lasezkay.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLSD:
- Clearside Biomedical reports Q3 EPS (15c), consensus (15c)
- Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- CLSD Upcoming Earnings Report: What to Expect?
- Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
- Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting